source
- Roche to acquire digital pathology firm PathAI in deal potentially worth over $1BRoche plans to offer PathAI’s tools as part of an effort to improve cancer diagnosis and tailored treatment.
- FDA reexamines previously rejected rare cancer therapy amid claims of political interferenceThe FDA has opened a new review of a treatment for a rare form of cancer that it had turned down a few months earlier. The reconsideration arrives as the agency faces fresh allegations that politi…